Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53
Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53
奥本海默以跑赢大盘的评级开始对Kymera Therapeutics进行报道,宣布目标股价为53美元
Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $53.
奥本海默分析师杰夫·琼斯开始对Kymera Therapeutics(纳斯达克股票代码:KYMR)进行报道,评级为跑赢大盘,并宣布目标股价为53美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。